Updated:
Adagene
Adagene was founded in 2011 by Peter Luo, its CEO, and Guoan Zhong, its chief research officer, with the explicit goal of redesigning antibody...
Adagene
Adagene was founded in 2011 by Peter Luo, its CEO, and Guoan Zhong, its chief research officer, with the explicit goal of redesigning antibody therapeutics from the ground up. The firm's technology originated from a computational biology insight: that dynamic conformational changes in antibodies — not just static binding — drive both efficacy and safety. This led to the development of the SAFEbody platform, a technology that masks antibody binding sites until they encounter the unique protease environment of a tumor, reducing systemic toxicity. The company's strategy bridges drug discovery and clinical development, with a focus on immuno-oncology assets that address well-defined but difficult targets. Its pipeline includes anti-CTLA-4 and anti-CD137 antibodies designed to widen the therapeutic index over first-generation competitors. In 2022, Adagene out-licensed its anti-CD137 candidate ADG106 to Sanofi for $17.5 million upfront, with potential milestones reaching over $2.5 billion (per company press release, 2022). Additional clinical-stage assets target CD40 and PD-L1, with trials enrolling patients in the United States, China, and Australia. Adagene operates dual headquarters in Suzhou, China, and San Francisco, California, reflecting a deliberate Sino-American structure for both discovery and clinical execution. The company raised $150 million in its February 2020 Nasdaq IPO and has since maintained a public-market presence under the ticker ADAG. Its strategic collaborations include a 2021 multi-target partnership with Exelixis worth up to $2.8 billion in potential milestones, showcasing the firm's role as a discovery engine for larger biopharmaceutical partners rather than a purely self-funded product company. What distinguishes Adagene structurally is its identity as a publicly traded platform company, not a traditional single-family office or venture fund. The firm's value rests on the SAFEbody and POWERbody computational platforms, which function like a technology licensing and partnership flywheel. This model means the firm's capital story is driven by upfront payments, milestone royalty economics, and equity-market valuation rather than AUM or fund-raises, putting it outside the conventional institutional allocation framework.
General information
Firm type
Asset Manager
Year founded
2011
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Suzhou
Corporate office
Suzhou, Jiangsu, China
Additional offices
San Francisco, CA, United States
Principals
Peter Luo
Co-founder, Chairman, and CEO
Guoan Zhong
Co-founder and Chief Research Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Adagene?
Capital allocation decisions are made by the company's Board of Directors and executive leadership, led by CEO Peter Luo. As a public operating company listed on Nasdaq (ADAG), Adagene deploys capital toward research and development, clinical trials, and its technology platforms rather than managing third-party investor capital like a fund.
How does Adagene source proprietary drug discovery opportunities?
Adagene generates its pipeline entirely from its in-house computational antibody platforms, SAFEbody and POWERbody. These tools screen billions of antibody variants using artificial intelligence to identify candidates with unique conformational dynamics, reducing reliance on external in-licensing for discovery-stage assets. The technology specifically targets epitopes considered inaccessible or undruggable by conventional methods.
Is Adagene a single-family office or a biotech company?
Adagene is a clinical-stage biotechnology company, not a family office. It was co-founded in 2011 by Peter Luo and Guoan Zhong and became a publicly listed company on Nasdaq in February 2020. The firm operates across drug discovery and clinical development, with headquarters in both Suzhou, China and San Francisco, California.
Does Adagene participate in fund commitments or only direct investments?
Adagene does not make LP fund commitments. As a drug development company, its capital is allocated directly to its own pipeline, platform technology, and collaborative research. Its financial model relies on equity issuance, strategic partnerships, and milestone payments from licensing deals rather than fund management.
What is Adagene's relationship with Sanofi and Exelixis?
Both are strategic collaboration partners. In March 2022, Sanofi licensed global rights to ADG106, Adagene's anti-CD137 agonist, for $17.5 million upfront with up to $2.5 billion in potential milestones. Exelixis entered a multi-target collaboration in February 2021 to discover novel masked antibody-drug candidates using the SAFEbody platform, with a deal value reaching up to $2.8 billion in milestones.
How is Adagene's wealth created and measured as a public company?
Wealth creation for shareholders stems from the appreciation of Adagene's Nasdaq-listed equity (ADAG) and the realization of milestones from its partnered pipeline assets. The company's founding wealth originated from scientific insight into dynamic antibody conformations paired with Chinese and US venture capital prior to its 2020 IPO.
What is Adagene's known posture on co-investments alongside external GPs?
Adagene is an operating biotech company, not an investment entity, so it does not participate in co-investments alongside general partners. Instead, its commercial posture involves co-development deals with pharmaceutical companies, where costs and profits are shared under structured licensing and milestone agreements.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: